Dónal Landers

Has grant

The University of Manchester
Country flagUnited Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

iDecide

Open Date: 2021-01-01

Close Date:

Grant: Close

Building Data Rich Clinical Trials

Open Date: 2021-01-01

Close Date: 2023-12-01

Articles (9)

Year:

2023

PURPOSE Matching patients with cancer to precision medicine clinical trials on the basis of their tumor genotype has the potential to improve outcomes for patients who have exhausted standard-of-care treatment options. However, the matching process presents a substantial challenge because of the number of clinical trials available. We describe a free, open source research tool designed to extract relevant trial information to support oncologists in the matching process, and we illustrate its utility with recent case studies of patients who were matched to trials using this tool. METHODS Trial records are sourced from ClinicalTrials.gov and indexed using natural language processing techniques, including named entity recognition, term normalization, and relationship extraction. Relationships between trials and genetic alterations are assigned scores on the basis of a rule-based system. All data are updated daily. A user interface is provided via R Shiny app. RESULTS An instance of the trial match tool, configured for UK clinical trials, is hosted by the digital Experimental Cancer Medicine Team (see link in Data Sharing Statement). Users select the relevant cancer type and genetic alteration(s). Matching studies are ranked according to the score assigned for the selected genetic alterations. Results may be downloaded and attached to the patient's health record if desired. The tool is currently being used to support the ongoing TARGET National study, which aims to match up to 6,000 patients to early phase clinical trials. We present three case studies that exemplify relationships between genetic alterations and studies. CONCLUSION With increasing numbers of precision medicine treatments and as comprehensive molecular profiling of tumor samples becomes more common, decision support tools are likely to become increasingly important. This work represents an important step toward the development and wider implementation of such systems.

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Andre Freitas

The University of Manchester

UNITED KINGDOM
View details

James Batchelor

University of Southampton

UNITED KINGDOM
View details

Javier García-Corbacho

-

SPAIN
View details

Matthew Krebs

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM
View details

Thomas Powles

Professor of Genitourinary Oncology

Queen Mary University of London

UNITED KINGDOM
View details

Iain Macpherson

Professor of Breast Oncology

-

UNITED KINGDOM
View details

Raoul Charles Coombes

Imperial College London

UNITED KINGDOM
View details

Philip Badman

Imperial College London

UNITED KINGDOM
View details

Florent Mouliere

Group Leader / Assistant Professor

VU medisch centrum

NETHERLANDS
View details

Alastair Watson

Cambridge University Hospitals NHS Foundation Trust

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.